New bisanthraquinone antibiotics and semi-synthetic derivatives with potent activity against clinical Staphylococcus aureus and Enterococcus faecium isolates

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 24, 2006, Pages 8446-8454

  Socha, Aaron M ^a   LaPlante, Kerry L ^a,b   Rowley, David C ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antibiotics; Bisanthraquinone; Marine streptomycete; Semi synthesis

Indexed keywords

ANTIBIOTIC AGENT; BACTERICIDE; BE 43472A; BE 43472B; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; DRUG ACTIVITY; DRUG POTENCY; ENTEROCOCCUS FAECIUM; HUMAN; HUMAN CELL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; STREPTOMYCETACEAE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTHRAQUINONES; ANTI-BACTERIAL AGENTS; CELLS, CULTURED; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TETRACYCLINE RESISTANCE; VANCOMYCIN RESISTANCE; VIRGINIAMYCIN;

ENTEROCOCCUS FAECIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA; STAPHYLOCOCCUS AUREUS;

EID: 33750496905     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.08.038     Document Type: Article

References (25)

1. National Nosocomial Infections Surveillance (NNIS) System, Am. J. Infect. Control 2004, 32, 470.
2. Rybak M.J., and LaPlante K.L. Pharmacotherapy 25 (2005) 74
3. Jensen P.R., Mincer T.J., Williams P.G., and Fenical W. Antonie van Leeuwenhoek 87 (2005) 43
4. Magarvey N.A., Keller J.M., Bernan V., Dworkin M., and Sherman D.H. Appl. Environ. Microbiol. 70 (2004) 7520
5. Mincer T.J., Jensen P.R., Kauffman C.A., and Fenical W. Appl. Environ. Microbiol. 68 (2002) 5005
6. Feling R.H., Buchanan G.O., Mincer T.J., Kauffman C.A., Jensen P.R., and Fenical W. Angew. Chem., Int. Ed. 42 (2003) 355
7. Kwon H.C., Kauffman C.A., Jensen P.R., and Fenical W. J. Am. Chem. Soc. 128 (2006) 1622
8. Socha A.M., Garcia D., Sheffer R., and Rowley D.C. J. Nat. Prod. 69 (2006) 1070
9. Kushida, H.; Nakajima, S.; Koyama, T.; Suzuki, H.; Ojiri, K.; Suda, H. Japan Patent JP 08143569, Kokai Tokkyo Koho, 1996, 10.
10. Clinical and Laboratory Standard Institute (CLSI) Performance standards for antimicrobial susceptibility testing M100-S15; CLSI, Ed.: Wayne, Pennsylvania, 2005.
11. Hamilton-Miller J.M. J. Antimicrob. Chemother. 27 (1991) 863
12. Jones R.N. Clin. Infect. Dis. 42 Suppl. 1 (2006) S13
13. Chopra I., and Roberts M. Microbiol. Mol. Biol. Rev. 65 (2001) 232
14. Connell S.R., Tracz D.M., Nierhaus K.H., and Taylor D.E. Antimicrob. Agents Chemother. 47 (2003) 3675
15. Mylonakis E., and Calderwood S.B. N. Eng. J. Med. 345 (2001) 1318
16. Quagliarello V.J., and Scheld W.M. N. Eng. J. Med. 336 (1997) 708
17. Voronenkov V.V., Vinogradov A.N., and Belyaev V.A. Russ. Chem. Rev. 39 (1970) 944
18. Wasserman H.H., and Ives J.L. Tetrahedron 37 (1981) 1825
19. Cardwell H.M.E., and McQuillin F.J. J. Chem. Soc. (1955) 525
20. da Silva M.J., Robles-Dutenhefner P., Menini L., and Gusevskaya E.V. J. Mol. Catal. A 201 (2003) 71
21. Okamoto I., Funaki W., Nakaya K., Kotani E., and Takeya T. Chem. Pharm. Bull. (Tokyo) 52 (2004) 756
22. Dombeck F., and Bracher F. Pharmazie 61 (2006) 387
23. Joshi E., Chordia M.D., Macdonald T.L., Linden J., and Olsson R. Bioorg. Med. Chem. Lett. 14 (2004) 929
24. LaPlante K.L., and Rybak M.J. Diagn. Microbiol. Infect. Dis. 50 (2004) 125
25. LaPlante K.L., and Rybak M.J. Antimicrob. Agents Chemother. 48 (2004) 4665